The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Epigenetic therapy of cancer
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CI-994 has undergone phase II clinical trials for advanced pancreatic cancer, nonsmall cell lung cancer and multiple myeloma, and phase III clinical trials in combination with gemcitabine for advanced nonsmall-cell lung and pancreatic cancers (discontinued).
“CI-994 has undergone phase II clinical trials for advanced pancreatic cancer, nonsmall cell lung cancer and multiple myeloma [18–20], and has been in phase III clinical trials in combination with gemcitabine for advanced nonsmall-cell lung and pancreatic cancers, though this trial was discontinued [20].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [20]
CI-994 is well tolerated and has undergone phase II/III clinical trials for several types of cancer.
“Importantly, CI-994 is well tolerated and has undergone phase II/III clinical trials for several types of cancer [18–20].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [20]
CI-994 is well tolerated.
“CI-994 is well tolerated and has undergone phase II/III clinical trials for several types of cancer [18–20].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [20]
CI-994 has undergone phase II/III clinical trials for several types of cancer.
“CI-994 is well tolerated and has undergone phase II/III clinical trials for several types of cancer [18–20].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [20]
Citations
Cites
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Role of TET enzymes in DNA methylation, development, and cancer
Rasmussen, K. D., & Helin, K. (2016) · Genes & Development · doi:10.1101/gad.276568.115 · Cited by 1,040
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Kruidenier, L., Chung, C.-W., Cheng, Z., Liddle, J., Che, K., Joberty, G., Bantscheff, M., Bountra, C., Bridges, A., Diallo, H., et al. (2012) · Nature · doi:10.1038/nature11262 · Cited by 950
A Phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention
Chen, A. C., Martin, A. J., Choy, B., Fernández-Peñas, P., Dalziell, R. A., McKenzie, C. A., Scolyer, R. A., Dhillon, H. M., Vardy, J. L., Kricker, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506197 · Cited by 648
Marine natural products as anticancer drugs
Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.333.4.2 · Cited by 597
Methyl-cpG-binding domain proteins: readers of the epigenome
Du, Q., Luu, P.-L., Stirzaker, C., & Clark, S. J. (2015) · Epigenomics · doi:10.2217/epi.15.39 · Cited by 544
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
Sirtuin functions and modulation: from chemistry to the clinic
Carafa, V., Rotili, D., Forgione, M., Cuomo, F., Serretiello, E., Hailu, G. S., Jarho, E., Lahtela-Kakkonen, M., Mai, A., & Altucci, L. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0224-3 · Cited by 387
Zebularine: a new drug for epigenetic therapy
Yoo, C. B., Cheng, J. C., & Jones, P. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320910 · Cited by 191
Baud, M. G. J., Leiser, T., Haus, P., Samlal, S., Wong, A. C., Wood, R. J., Petrucci, V., Gunaratnam, M., Hughes, S. M., Buluwela, L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2016182 · Cited by 100
Flagged first, then by citations
Research works printed but not linked: 186
- Berger, 2009, Genes Dev., 23, 781, 10.1101/gad.1787609 · DOI
- For selected reviews, see: (a) Yoo, C.B.; Jones, P.A. Nat. Rev. Drug Discov. 2006, 5, 37. · DOI
- (a) Yoo, C.B.; Jones, P.A. Nat. Rev. Drug Discov. 2006, 5, 37. · DOI
- Mair, 2014, Trends Pharmacol. Sci., 35, 136, 10.1016/j.tips.2014.01.001 · DOI
- Bates, 2020, N. Engl. J. Med., 383, 650, 10.1056/NEJMra1805035 · DOI
- For a monograph, see: Arimondo, P.; Egger, G. (Eds.). Drug Discovery in Cancer Epigenetics. Academic Press, 2016.
- Lyko, 2005, J. Natl. Cancer Inst., 97, 1498, 10.1093/jnci/dji311 · DOI
- For reviews of DNA methyltransferase inhibitors, see: (a) Ren, J.; Singh, B.N.; Huang, Q.; Li, Z.; Gao, Y.; Mishra, P.; Hwa, Y.L.; Li, J.; Dowdy, S.C.; Jiang, S.-W. Cell. Signal. 2011, 23, 1082. · DOI
- (a) Ren, J.; Singh, B.N.; Huang, Q.; Li, Z.; Gao, Y.; Mishra, P.; Hwa, Y.L.; Li, J.; Dowdy, S.C.; Jiang, S.-W. Cell. Signal. 2011, 23, 1082. · DOI
- Fahy, 2012, Expert Opin. Ther. Pat., 22, 1427, 10.1517/13543776.2012.729579 · DOI
- Gros, 2012, Biochimie, 94, 2280, 10.1016/j.biochi.2012.07.025 · DOI
- Pechalrieu, 2017, Biochem. Pharmacol., 129, 1, 10.1016/j.bcp.2016.12.004 · DOI
- Agrawal, 2018, Pharmacol. Ther., 188, 45, 10.1016/j.pharmthera.2018.02.006 · DOI
- Kaminskas, 2005, Oncologist, 10, 176, 10.1634/theoncologist.10-3-176 · DOI
- Gowher, 2004, Cancer Biol. Ther., 3, 1062, 10.4161/cbt.3.11.1308 · DOI
- Issa, 2005, Nat. Rev. Drug Discov., 4, S6, 10.1038/nrd1726 · DOI
- Kaminskas, 2005, Clin. Cancer Res., 11, 3604, 10.1158/1078-0432.CCR-04-2135 · DOI
- Kuykendall, 2005, Ann. Pharmacother., 39, 1700, 10.1345/aph.1E612 · DOI
- Issa, 2005, J. Clin. Oncol., 23, 3948, 10.1200/JCO.2005.11.981 · DOI
- Stresemann, 2006, Cancer Res., 66, 2794, 10.1158/0008-5472.CAN-05-2821 · DOI
- Qu, 2010, J. Biol. Chem., 285, 11786, 10.1074/jbc.M109.086561 · DOI
- Xu, 2007, Cancer Res., 67, 1203, 10.1158/0008-5472.CAN-06-2310 · DOI
- Hill, 2021, Semin. Hematol., 58, 35, 10.1053/j.seminhematol.2020.11.008 · DOI
- Matoušová, 2011, Epigenetics, 6, 769, 10.4161/epi.6.6.16215 · DOI
- Holleran, 2015, Cancer Chemother. Pharmacol., 76, 803, 10.1007/s00280-015-2857-x · DOI
- Young, 2019, J. Nucl. Med., 60, 492, 10.2967/jnumed.118.216994 · DOI
- Dhingra, 2004, Investig. New Drugs, 9, 69, 10.1007/BF00194548 · DOI
- Agrawal, 2017, Cytometry A, 91, 133, 10.1002/cyto.a.23004 · DOI
- Zhou, 2002, J. Mol. Biol., 321, 591, 10.1016/S0022-2836(02)00676-9 · DOI
- Champion, 2010, PLoS One, 5, 10.1371/journal.pone.0012388 · DOI
- Takemura, 2018, Biosci. Biotechnol. Biochem., 82, 1, 10.1080/09168451.2018.1459466 · DOI
- Cheng, 2004, Cancer Cell, 6, 151, 10.1016/j.ccr.2004.06.023 · DOI
- Jeong, 1998, J. Med. Chem., 41, 2572, 10.1021/jm980111x · DOI
- O’Sullivan Coyne, 2016, Ann. Oncol., 27
- Adès, 2019, Lancet Hematol., 6, E290, 10.1016/S2352-3026(19)30079-1 · DOI
- Fang, 2003, Cancer Res., 63, 7563
- Elbling, 2005, FASEB J., 19, 807, 10.1096/fj.04-2915fje · DOI
- Lin, 2011, J. Biomed. Sci., 18, 3, 10.1186/1423-0127-18-3 · DOI
- Brueckner, 2005, Cancer Res., 65, 6305, 10.1158/0008-5472.CAN-04-2957 · DOI
- Ou, 2018, Oncol. Rep., 39, 993
- Yoo, 2013, PLoS One, 8
- García-Domínguez, 2013, Bioorg. Med. Chem. Lett., 23, 1631, 10.1016/j.bmcl.2013.01.085 · DOI
- Sun, 2018, Oncol. Lett., 16, 5799
- For a review, see: Medina-Franco, J.L.; Caulfield, T. Drug Discov. Today 2011, 16, 418. · DOI
- Siedlecki, 2003, Biochem. Biophys. Res. Commun., 306, 558, 10.1016/S0006-291X(03)01000-3 · DOI
- Savickiene, 2012, Cell Biol. Int., 36, 1067, 10.1042/CBI20110649 · DOI
- Yoo, 2012, Adv. Prot. Chem. Struct. Biol., 87, 219, 10.1016/B978-0-12-398312-1.00008-1 · DOI
- An, 2017, Exp. Mol. Med., 49, 10.1038/emm.2017.5 · DOI
- Koli, 2013, Nature, 502, 472, 10.1038/nature12750 · DOI · Paper page
- Chua, 2019, ACS Med. Chem. Lett., 10, 180, 10.1021/acsmedchemlett.8b00474 · DOI
- Jakubek, 2019, Bioorg. Chem., 88, 10.1016/j.bioorg.2019.02.034 · DOI
- Neja, 2020, Epigenetics Insights, 13, 1, 10.1177/2516865720964808 · DOI
- Cosenza, 2018, Int. J. Mol. Sci., 19, 2337, 10.3390/ijms19082337 · DOI
- For representative reviews of histone acetylase inhibitors, see: (a) Monneret, C. Eur. J. Med. Chem. 2005, 40, 1. · DOI
- Moradei, 2005, Curr. Med. Chem.-Anti-Cancer Agents, 5, 529, 10.2174/1568011054866946 · DOI
- Carey, 2006, Curr. Opin. Pharmacol., 6, 369, 10.1016/j.coph.2006.03.010 · DOI
- Marchion, 2007, Expert. Rev. Anticancer. Ther., 7, 583, 10.1586/14737140.7.4.583 · DOI
- Falkenberg, 2014, Nat. Rev. Drug Discov., 13, 673, 10.1038/nrd4360 · DOI · Paper page
- Benton, 2017, Cancer J., 23, 286, 10.1097/PPO.0000000000000284 · DOI
- Arlt, 2016, Expert Opin. Investig. Drugs, 25, 1251, 10.1080/13543784.2016.1240167 · DOI
- Suraweera, 2018, Front. Oncol., 8, art. 92, 10.3389/fonc.2018.00092 · DOI
- Halsall, 2016, BioEssays, 38, 1102, 10.1002/bies.201600070 · DOI
- Zwergel, 2016, Clin. Epigenetics, 2, 7
- Nijhuis, 2019, Front. Immunol., 10, 10.3389/fimmu.2019.00151 · DOI
- Mrakovcic, 2017, Int. J. Mol. Sci., 18, 1883, 10.3390/ijms18091883 · DOI
- Flinnin, 1999, Nature, 401, 188, 10.1038/43710 · DOI · Paper page
- Khanwani, 2001, Proc. Am. Soc. Clin. Oncol., 20, 86a
- Raffoux, 2005, Haematologica, 90, 986
- Reid, 2004, Lung Cancer, 45, 381, 10.1016/j.lungcan.2004.03.002 · DOI
- Duvic, 2007, Blood, 109, 31, 10.1182/blood-2006-06-025999 · DOI · Paper page
- Marks, 2007, Nat. Biotechnol., 25, 84, 10.1038/nbt1272 · DOI
- Rodríguez-Paredes, 2011, Nat. Med., 17, 330, 10.1038/nm.2305 · DOI
- Duvic, 2016, J. Clin. Oncol., 34, 7562, 10.1200/JCO.2016.34.15_suppl.7562 · DOI
- Abbott, 2019, Mol. Pharmacol., 95, 324, 10.1124/mol.118.114587 · DOI
- Giles, 2006, Clin. Cancer Res., 12, 4628, 10.1158/1078-0432.CCR-06-0511 · DOI
- Maiso, 2006, Cancer Res., 66, 5781, 10.1158/0008-5472.CAN-05-4186 · DOI
- Kaufman, 2019, Blood Cancer J., 9, 3, 10.1038/s41408-018-0154-8 · DOI
- De Bono, 2008, Clin. Cancer Res., 14, 6663, 10.1158/1078-0432.CCR-08-0376 · DOI
- Evens, 2016, Clin. Cancer Res., 22, 1059, 10.1158/1078-0432.CCR-15-0624 · DOI
- García-Manero, 2019, Blood Adv., 3, 508, 10.1182/bloodadvances.2018027409 · DOI
- Sumanadasa, 2012, Antimicrob. Agents Chemother., 56, 3849, 10.1128/AAC.00030-12 · DOI
- Wu, 2010, PLoS One, 5, 10.1371/annotation/f67a90fb-3e4e-4484-bffe-fcfafbfe88c7 · DOI
- Zhao, 2018, Oncoscience, 5, 196, 10.18632/oncoscience.420 · DOI
- Finazzi, 2013, Br. J. Haematol., 161, 688, 10.1111/bjh.12332 · DOI
- Comi, 2018, Neurology, 90
- He, 2018, Int. J. Biol. Sci., 14, 1845, 10.7150/ijbs.27661 · DOI
- Popat, 2016, Blood, 128, 3321, 10.1182/blood.V128.22.3321.3321 · DOI
- Galloway, 2015, Clin. Cancer Res., 21, 1566, 10.1158/1078-0432.CCR-14-2820 · DOI
- Valencia, 2016, J. Clin. Oncol., 34, 2558, 10.1200/JCO.2016.34.15_suppl.2558 · DOI
- Bjornsson, 2014, Sci. Transl. Med., 6, 256ra135, 10.1126/scitranslmed.3009278 · DOI
- Undevia, 2004, Ann. Oncol., 15, 1705, 10.1093/annonc/mdh438 · DOI
- Whittaker, 2010, J. Clin. Oncol., 28, 4485, 10.1200/JCO.2010.28.9066 · DOI
- Coiffier, 2012, J. Clin. Oncol., 30, 631, 10.1200/JCO.2011.37.4223 · DOI
- Byrd, 2005, Blood, 105, 959, 10.1182/blood-2004-05-1693 · DOI
- Brunvand, 2018, Hematol. Oncol., 36, 340, 10.1002/hon.2421 · DOI
- Cheung, 2019, Haematologica, 104
- Furamai, 2002, Cancer Res., 62, 4916
- Chen, 2018, Org. Process. Res. Dev., 22, 190, 10.1021/acs.oprd.7b00352 · DOI
- Taunton, 1996, Science, 272, 408, 10.1126/science.272.5260.408 · DOI · Paper page
- Kwon, 2002, J. Biol. Chem., 277, 2073, 10.1074/jbc.M106699200 · DOI
- Buoncervello, 2012, Neoplasia, 14, 855, 10.1593/neo.121020 · DOI
- Komatsu, 2001, Cancer Res., 61, 4459
- Murakami, 2010, Oncology, 78, 62, 10.1159/000292362 · DOI
- Witta, 2012, J. Clin. Oncol., 30, 2248, 10.1200/JCO.2011.38.9411 · DOI
- Yeruva, 2018, NPJ Breast Cancer, 4, 1, 10.1038/s41523-017-0053-3 · DOI
- Azad, 2018, J. Clin. Oncol., 36, 3557, 10.1200/JCO.2018.36.15_suppl.3557 · DOI
- Brunetto, 2013, Clin. Cancer Res., 19, 5494, 10.1158/1078-0432.CCR-13-0735 · DOI
- Batlevi, 2017, Br. J. Haematol., 178, 434, 10.1111/bjh.14698 · DOI
- Grivas, 2019, Cancer, 125, 533, 10.1002/cncr.31817 · DOI
- Pan, 2014, Med. Chem. Commun., 5, 1789, 10.1039/C4MD00350K · DOI
- García, 2011, Bioorg. Med. Chem., 19, 3637, 10.1016/j.bmc.2010.12.026 · DOI
- Shima, 2004, Cancer Lett., 203, 163, 10.1016/j.canlet.2003.08.036 · DOI
- Altonsy, 2012, Nutr. Cancer, 64, 1251, 10.1080/01635581.2012.721156 · DOI
- Myzak, 2004, Cancer Res., 64, 5767, 10.1158/0008-5472.CAN-04-1326 · DOI
- Ho, 2009, J. Nutr., 139, 2393, 10.3945/jn.109.113332 · DOI
- Welsbie, 2009, Cancer Res., 69, 958, 10.1158/0008-5472.CAN-08-2216 · DOI
- Wawruszak, 2019, Cancers (Basel), 11, 10.3390/cancers11020148 · DOI
- McLeod, 2018, Prostate, 78, 266, 10.1002/pros.23467 · DOI
- Isaacs, 2013, Cancer Res., 3, 1386, 10.1158/0008-5472.CAN-12-2730 · DOI · Paper page
- Bosch-Presegué, 2011, Genes Cancer, 2, 648, 10.1177/1947601911417862 · DOI
- For a review, see: Sebastián, C.; Satterstrom, F.K.; Halgis, M.C.; Mostosiavsky, R. J. Biol Chem. 2012, 287, 4244. · DOI · Paper page
- Sauve, 2010, Biochim. Biophys. Acta, 1804, 1591, 10.1016/j.bbapap.2010.01.021 · DOI
- Cen, 2010, Biochim. Biophys. Acta, 1804, 1635, 10.1016/j.bbapap.2009.11.010 · DOI
- Shi, 2013, J. Phys. Chem. Lett., 4, 491, 10.1021/jz302015s · DOI
- Hirsch, 2011, Mol. BioSyst., 7, 16, 10.1039/C0MB00033G · DOI
- For reviews, see: (a) Carafa, V.; Rotili, D.; Forgione, M.; Cuomo, F.; Serretiello, E.; Hailu, G.A. et al. Clin. Epigenetics 2016, 8, 61.
- Carafa, 2019, Front. Pharmacol., 10, 38, 10.3389/fphar.2019.00038 · DOI
- Ávalos, 2005, Mol. Cell, 17, 855, 10.1016/j.molcel.2005.02.022 · DOI
- Ota, 2006, Oncogene, 25, 176, 10.1038/sj.onc.1209049 · DOI
- Lara, 2009, Oncogene, 28, 781, 10.1038/onc.2008.436 · DOI
- Solomon, 2006, Mol. Cell. Biol., 26, 28, 10.1128/MCB.26.1.28-38.2006 · DOI
- Peck, 2010, Mol. Cancer Ther., 9, 844, 10.1158/1535-7163.MCT-09-0971 · DOI
- Gertza, 2013, Proc. Natl. Acad. Sci. U. S. A., 110, E2772
- Schuetz, 2007, Structure, 15, 377, 10.1016/j.str.2007.02.002 · DOI
- Trapp, 2007, ChemMedChem, 2, 1419, 10.1002/cmdc.200700003 · DOI
- Yuan, 2017, Oncotarget, 8, 14912, 10.18632/oncotarget.14741 · DOI
- Ong, 2018, Ageing Res. Rev., 43, 64, 10.1016/j.arr.2018.02.004 · DOI
- For representative reviews, see: (a) Filippakopoulos, P.; Knapp, S. Nat. Rev. Drug Discov. 2014, 13, 337. · DOI
- (a) Filippakopoulos, P.; Knapp, S. Nat. Rev. Drug Discov. 2014, 13, 337. · DOI
- Gallenkamp, 2014, ChemMedChem, 9, 438, 10.1002/cmdc.201300434 · DOI
- Sánchez, 2014, Biochim. Biophys. Acta - Gene Regul. Mech., 1839, 676, 10.1016/j.bbagrm.2014.03.011 · DOI
- Ferri, 2016, Biochem. Pharmacol., 106, 1, 10.1016/j.bcp.2015.12.005 · DOI
- Pérez-Salvia, 2017, Epigenetics, 12, 323, 10.1080/15592294.2016.1265710 · DOI
- Ali, 2017, Recent Pat. Anticancer Drug Discov., 12, 340, 10.2174/1574892812666170808121228 · DOI
- Doroshow, 2017, Ann. Oncol., 28, 1776, 10.1093/annonc/mdx157 · DOI
- Bhattacharya, 2018, Clin. Adv. Haematol. Oncol., 16, 504
- Alqahtani, 2019, Future Sci. OA, 5, FSO372, 10.4155/fsoa-2018-0115 · DOI
- Wu, 2019, Nat. Commun., 10
- For a review of diazepine derivatives as bromodomain inhibitors, see: Smith, S.G.; Sánchez, R.; Zhou, M.M. Chem. Biol. 2014, 21, 573. · DOI
- Nicodeme, 2010, Nature, 468, 1119, 10.1038/nature09589 · DOI · Paper page
- For a specific review of compounds targeting BDR4, see: Liu, Z.; Wang, P.; Chen, H.; Wold, E.A.; Tian, B.; Brasier, A.R.; Zhou, J. J. Med. Chem. 2017, 60, 4533. · DOI
- Zuber, 2011, Nature, 478, 524, 10.1038/nature10334 · DOI · Paper page
- Filippakopoulos, 2010, Nature, 468, 1067, 10.1038/nature09504 · DOI · Paper page
- Matzuk, 2012, Cell, 150, 673, 10.1016/j.cell.2012.06.045 · DOI
- For a review of the discovery of CPI-0610, see: Albrecht, B.K.; Gehling, V.S.; Hewitt, M.C.; Vaswani, R.G.; Côté, A. et al. J. Med. Chem. 2016, 59, 1330. · DOI
- Mirguet, 2013, J. Med. Chem., 56, 7501, 10.1021/jm401088k · DOI
- Piha-Paul, 2020, JNCI Cancer Spectr., 4, pkz093, 10.1093/jncics/pkz093 · DOI
- For a review of clinical studies of bromodomain inhibitors, see: Sun, Y.; Han, J.; Wang, Z.; Li, X.; Sun, Y.; Hu, Z. Front. Pharmacol. 2021, 11, 621093.
- Floyd, 2013, Nature, 12147
- Varier, 2011, Biochem. Biophys. Acta (BBA)-Rev. Cancer, 1815, 75
- Greer, 2012, Nat. Rev. Genetics, 13, 343, 10.1038/nrg3173 · DOI · Paper page
- Enroth, 2011, BMC Cancer, 11, 450, 10.1186/1471-2407-11-450 · DOI
- Pan, 2018, Cell Mol. Life Sci., 75, 209, 10.1007/s00018-017-2596-8 · DOI
- Miranda, 2009, Mol. Cancer Ther., 8, 1579, 10.1158/1535-7163.MCT-09-0013 · DOI
- Kikuchi, 2012, Lung Cancer, 78, 138, 10.1016/j.lungcan.2012.08.003 · DOI
- Asangani, 2013, Mol. Cell, 49, 180, 10.1016/j.molcel.2012.10.008 · DOI
- Munshi, 2013, Clin. Cancer Res.
- Koutsodontis, 2004, Oncogene, 23, 9190, 10.1038/sj.onc.1208141 · DOI
- Højfeldt, 2013, Nat. Rev. Drug Discov., 12, 917, 10.1038/nrd4154 · DOI
- Yu, 2013, J. Phys. Chem. B, 117, 8422, 10.1021/jp404292t · DOI
- Vintém, 2005, Bioorg. Med. Chem., 13, 3487, 10.1016/j.bmc.2005.02.061 · DOI
- Mimasu, 2010, Biochemistry, 49, 6494, 10.1021/bi100299r · DOI
- Maes, 2013, J. Clin. Oncol., 31
- Salamero, 2020, J. Clin. Oncol., 38, 4260, 10.1200/JCO.19.03250 · DOI
- Lohse, 2011, Bioorg. Med. Chem., 19, 3625, 10.1016/j.bmc.2011.01.046 · DOI
- For a review, see: Wright, M.; Brennan, P.E.; Kawamura, A. Inhibitors of JmjC-Containing Histone Demethylases, in: Mai, A. (ed) Chemical Epigenetics. Topics in Medicinal Chemistry, Vol. 33, pp. 221-253. Springer, 2019. · DOI
- Park, 2016, Pharmacol. Res., 105, 146, 10.1016/j.phrs.2016.01.026 · DOI
- Morel, 2020, Nat. Rev. Clin. Oncol., 17, 91, 10.1038/s41571-019-0267-4 · DOI
- For a review of multitarget epigenetic agents, see: de Lera, A.R.; Ganesan, A. Curr. Opin. Chem. Biol. 2020, 57, 135. · DOI
- Rechavi, 2016, TheScientist
- Ferreira, 2018, Cancer Metastasis Rev., 37, 55, 10.1007/s10555-017-9715-8 · DOI
- Pan, 2018, Hematol. Oncol., 11, 48, 10.1186/s13045-018-0590-8 · DOI
- Sun, 2019, Biomed. Pharmacother., 112
- For a review, see: Helin, K.; Dhanak, D. Nature 2013, 502, 480. · DOI
- Hou, 2012, Am. J. Transl. Res., 4, 247
- Amatu, 2013, Clin. Cancer Res., 19, 1, 10.1158/1078-0432.CCR-12-3518 · DOI
Cited by
Sorted by citations
Lu, W., Kawatani, K., Ren, Y., Nambara, T., Jia, L., Jeevaratnam, S., Lee, E., Martinez, P. R., Izhar, T., Wang, N., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-01982-0 · Cited by 4
Metadata
- Authors
- Avendaño, C., & Menéndez, J. C.
- ORCID
- Menéndez, J. Carlos
- Venue
- Medicinal Chemistry of Anticancer Drugs
- Publisher
- Elsevier
- Published
- 2023
- Pages
- 389-444
- OpenAlex
- W4375929510
- Cited by
- 4
- References
- 11
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 1.60
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- Locations
- Elsevier eBooks (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- epigenetic therapy, cancer, epigenetic modulation, DNA methylation, histone modifications, chromatin remodeling, gene silencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
